Related references
Note: Only part of the references are listed.Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction
Andy C. Rawstron et al.
BLOOD (2015)
Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium
Ola Landgren et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma
Joaquin Martinez-Lopez et al.
BLOOD (2014)
Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry
N. Puig et al.
LEUKEMIA (2014)
Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders
M. Ladetto et al.
LEUKEMIA (2014)
Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma
Aristeidis Chaidos et al.
BLOOD (2013)
Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile
Bruno Paiva et al.
BLOOD (2013)
Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study
Joaquin Martinez-Lopez et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study
Andy C. Rawstron et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma
G. Bianchi et al.
LEUKEMIA (2013)
A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control
B. Paiva et al.
LEUKEMIA (2013)
Minimal residual disease quantification using consensus primers and high- throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia
A. C. Logan et al.
LEUKEMIA (2013)
How should we treat newly diagnosed multiple myeloma patients?
Maria-Victoria Mateos et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2013)
Multiparameter Flow Cytometry Evaluation of Plasma Cell DNA Content and Proliferation in 595 Transplant-Eligible Patients with Myeloma Included in the Spanish GEM2000 and GEM2005<65y Trials
Bruno Paiva et al.
AMERICAN JOURNAL OF PATHOLOGY (2012)
High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma
Bruno Paiva et al.
BLOOD (2012)
Kappa deleting element as an alternative molecular target for minimal residual disease assessment by real-time quantitative PCR in patients with multiple myeloma
Noemi Puig et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2012)
Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients
B. Paiva et al.
LEUKEMIA (2012)
High-Throughput Sequencing Detects Minimal Residual Disease in Acute T Lymphoblastic Leukemia
David Wu et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple Myeloma
Bruno Paiva et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma
B. Paiva et al.
LEUKEMIA (2011)
The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients
Bruno Paiva et al.
BLOOD (2009)
Contamination of autologous peripheral blood progenitor cell grafts predicts overall survival after high-dose chemotherapy in multiple myeloma
H. G. Kopp et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2009)
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation
Bruno Paiva et al.
BLOOD (2008)
Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders
Andy C. Rawstron et al.
HAEMATOLOGICA (2008)
International uniform response criteria for multiple myeloma
B. G. M. Durie et al.
LEUKEMIA (2006)
Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system
D Dingli et al.
BLOOD (2006)
Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma
GS Nowakowski et al.
BLOOD (2005)
Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance
S Kumar et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects
VHJ van der Velden et al.
LEUKEMIA (2003)
Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation
AC Rawstron et al.
BLOOD (2002)
Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome
JF San Miguel et al.
BLOOD (2002)
Share Paper
